Metabolomics of pulmonary exacerbations reveals the personalized nature of cystic fibrosis disease
Background. Cystic fibrosis (CF) is a genetic disease that results in chronic infections of the lungs. CF patients experience intermittent pulmonary exacerbations (CFPE) that are associated with poor clinical outcomes. CFPE involves an increase in disease symptoms requiring more aggressive therapy....
Main Authors: | Robert A. Quinn, Yan Wei Lim, Tytus D. Mak, Katrine Whiteson, Mike Furlan, Douglas Conrad, Forest Rohwer, Pieter Dorrestein |
---|---|
Format: | Article |
Language: | English |
Published: |
PeerJ Inc.
2016-08-01
|
Series: | PeerJ |
Subjects: | |
Online Access: | https://peerj.com/articles/2174.pdf |
Similar Items
-
High-Resolution Longitudinal Dynamics of the Cystic Fibrosis Sputum Microbiome and Metabolome through Antibiotic Therapy
by: Ruma Raghuvanshi, et al.
Published: (2020-06-01) -
Microbial contamination of home nebulizers in children with cystic fibrosis and clinical implication on the number of pulmonary exacerbations
by: Seyed Ahmad Tabatabaii, et al.
Published: (2020-02-01) -
The Fitter the Better? Cardiopulmonary Exercise Testing Can Predict Pulmonary Exacerbations in Cystic Fibrosis
by: Asterios Kampouras, et al.
Published: (2021-06-01) -
Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis
by: Jordana E. Hoppe, et al.
Published: (2017-12-01) -
Cystic Fibrosis Rapid Response: Translating Multi-omics Data into Clinically Relevant Information
by: Ana Georgina Cobián Güemes, et al.
Published: (2019-04-01)